These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 21222643)

  • 1. Chronic inflammatory disorders and accelerated atherosclerosis: chronic kidney disease.
    Navab KD; Elboudwarej O; Gharif M; Yu J; Hama SY; Safarpour S; Hough GP; Vakili L; Reddy ST; Navab M; Vaziri ND
    Curr Pharm Des; 2011; 17(1):17-20. PubMed ID: 21222643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease.
    Vaziri ND
    J Ren Nutr; 2010 Sep; 20(5 Suppl):S35-43. PubMed ID: 20797569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dual nature of HDL: Anti-Inflammatory and pro-Inflammatory.
    Namiri-Kalantari R; Gao F; Chattopadhyay A; Wheeler AA; Navab KD; Farias-Eisner R; Reddy ST
    Biofactors; 2015 May; 41(3):153-9. PubMed ID: 26072738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salutary effects of hemodialysis on low-density lipoprotein proinflammatory and high-density lipoprotein anti-inflammatory properties in patient with end-stage renal disease.
    Vaziri ND; Navab K; Gollapudi P; Moradi H; Pahl MV; Barton CH; Fogelman AM; Navab M
    J Natl Med Assoc; 2011 Jun; 103(6):524-33. PubMed ID: 21830637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide.
    Vaziri ND; Moradi H; Pahl MV; Fogelman AM; Navab M
    Kidney Int; 2009 Aug; 76(4):437-44. PubMed ID: 19471321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ApoA-1 mimetic peptide reverses uremia-induced upregulation of pro-atherogenic pathways in the aorta.
    Vaziri ND; Bai Y; Yuan J; Said HL; Sigala W; Ni Z
    Am J Nephrol; 2010; 32(3):201-211. PubMed ID: 20639628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of dysfunctional HDL in atherosclerosis.
    Navab M; Reddy ST; Van Lenten BJ; Anantharamaiah GM; Fogelman AM
    J Lipid Res; 2009 Apr; 50 Suppl(Suppl):S145-9. PubMed ID: 18955731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal.
    Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Datta G; Garber D; Fogelman AM
    Curr Opin Lipidol; 2004 Dec; 15(6):645-9. PubMed ID: 15529023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral amphipathic peptides as therapeutic agents.
    Reddy ST; Anantharamaiah GM; Navab M; Hama S; Hough G; Grijalva V; Garber DW; Datta G; Fogelman AM
    Expert Opin Investig Drugs; 2006 Jan; 15(1):13-21. PubMed ID: 16370930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential restoration of HDL function with apolipoprotein A-I mimetic peptide in end-stage renal disease.
    Kaysen GA
    Kidney Int; 2009 Aug; 76(4):359-61. PubMed ID: 19644477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proatherogenic high-density lipoprotein, vascular inflammation, and mimetic peptides.
    Yu R; Yekta B; Vakili L; Gharavi N; Navab M; Marelli D; Ardehali A
    Curr Atheroscler Rep; 2008 Apr; 10(2):171-6. PubMed ID: 18417073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDL apolipoprotein-related peptides in the treatment of atherosclerosis and other inflammatory disorders.
    Getz GS; Wool GD; Reardon CA
    Curr Pharm Des; 2010; 16(28):3173-84. PubMed ID: 20687877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid disorders and their relevance to outcomes in chronic kidney disease.
    Vaziri ND; Norris K
    Blood Purif; 2011; 31(1-3):189-96. PubMed ID: 21228589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of HDL dysfunction in end-stage renal disease: a double-edged sword.
    Moradi H; Vaziri ND; Kashyap ML; Said HM; Kalantar-Zadeh K
    J Ren Nutr; 2013 May; 23(3):203-6. PubMed ID: 23611547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms.
    Navab M; Reddy ST; Van Lenten BJ; Fogelman AM
    Nat Rev Cardiol; 2011 Apr; 8(4):222-32. PubMed ID: 21304474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The paradox of dysfunctional high-density lipoprotein.
    Ansell BJ; Fonarow GC; Fogelman AM
    Curr Opin Lipidol; 2007 Aug; 18(4):427-34. PubMed ID: 17620860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond LDL-cholesterol: HDL-cholesterol as a target for atherosclerosis prevention.
    Parhofer KG
    Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):414-7. PubMed ID: 16151973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular Mechanism and Evaluation Method for Anti-Inflammatory HDL].
    Tanaka N; Ishida T
    Rinsho Byori; 2016 Jan; 64(1):49-56. PubMed ID: 27192797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of disease: proatherogenic HDL--an evolving field.
    Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Ansell BJ; Fogelman AM
    Nat Clin Pract Endocrinol Metab; 2006 Sep; 2(9):504-11. PubMed ID: 16957764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased monocyte adhesion-promoting capacity of plasma in end-stage renal disease - response to antioxidant therapy.
    Moradi H; Ganji S; Kamanna V; Pahl MV; Vaziri ND
    Clin Nephrol; 2010 Oct; 74(4):273-81. PubMed ID: 20875379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.